Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

AptaBio Therapeutics Inc (293780)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6,210 +20    +0.32%
03/05 - Closed. Currency in KRW ( Disclaimer )
  • Volume: 80,806
  • Bid/Ask: 6,210 / 6,220
  • Day's Range: 6,070 - 6,440
Type:  Equity
Market:  South Korea
ISIN:  KR7293780003 
AptaBio Therapeutics 6,210 +20 +0.32%

293780 Balance Sheet

 
Featured here, the Balance Sheet for AptaBio Therapeutics Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2022
31/12
Total Current Assets 57474.4 71996.65 - -
Cash and Short Term Investments 52885.3 66458.21 - -
Cash - - - -
Cash & Equivalents 25016.26 33622.69 - -
Short Term Investments 19000 24000 - -
Total Receivables, Net 2658.58 2464.18 - -
Accounts Receivables - Trade, Net - - - -
Total Inventory - - - -
Prepaid Expenses 176.31 47.55 - -
Other Current Assets, Total 1754.21 3026.72 - -
Total Assets 92519.12 100944.95 - -
Property/Plant/Equipment, Total - Net 5129.14 5866.15 - -
Property/Plant/Equipment, Total - Gross 6403.48 7065.95 - -
Accumulated Depreciation, Total -1274.34 -1199.8 - -
Goodwill, Net - - - -
Intangibles, Net 61.09 27.11 - -
Long Term Investments 23779.38 18686.8 - -
Note Receivable - Long Term 366.31 154.91 - -
Other Long Term Assets, Total 3675.11 1968.24 - -
Other Assets, Total 31656.94 38107.32 - -
Total Current Liabilities 817.95 3279.34 - -
Accounts Payable - - - -
Payable/Accrued - - - -
Accrued Expenses 337.19 322.06 - -
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 131.08 130.12 - -
Other Current liabilities, Total 349.69 2827.17 - -
Total Liabilities 31155.72 36889.11 - -
Total Long Term Debt 13802.9 16866.58 - -
Long Term Debt 13569.45 16600.02 - -
Capital Lease Obligations 233.45 266.56 - -
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total 16534.87 16743.19 - -
Total Equity 61363.39 64055.84 - -
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net 518.79 518.79 - -
Common Stock, Total 11149.43 11149.43 - -
Additional Paid-In Capital 129711.99 131075.37 - -
Retained Earnings (Accumulated Deficit) -80713.2 -79263.14 - -
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 696.38 575.39 - -
Total Liabilities & Shareholders' Equity 92519.12 100944.95 - -
Total Common Shares Outstanding 23.79 22.3 22.3 22.32
Total Preferred Shares Outstanding - - - -
* In Millions of KRW (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

293780 Comments

Write your thoughts about AptaBio Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email